ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1NTRA | NATERA INC | Healthcare | $46.83B | 16.98% |
2ILMN | ILLUMINA INC | Healthcare | $31.68B | 11.49% |
3GH | GUARDANT HEALTH INC | Healthcare | $20.95B | 7.60% |
4HALO | HALOZYME THERAPEUTICS INC | Healthcare | $11.48B | 4.16% |
5CORT | CORCEPT THERAPEUTICS INC | Healthcare | $8.07B | 2.93% |
6CYTK | CYTOKINETICS INC | Healthcare | $7.82B | 2.84% |
7TXG | 10X GENOMICS INC | Healthcare | $7.77B | 2.82% |
8TWST | TWIST BIOSCIENCE CORP | Healthcare | $7.16B | 2.60% |
9CAI | CARIS LIFE SCIENCES INC | Healthcare | $6.87B | 2.49% |
10ARWR | ARROWHEAD PHARMACEUTICALS INC | Healthcare | $6.66B | 2.42% |
11IBRX | IMMUNITYBIO INC | Healthcare | $6.46B | 2.34% |
12GRAL | GRAIL INC | Healthcare | $5.46B | 1.98% |
13SHC | SOTERA HEALTH CO | Healthcare | $4.66B | 1.69% |
14IONS | IONIS PHARMACEUTICALS INC | Healthcare | $4.55B | 1.65% |
15DFTX | DEFINIUM THERAPEUTICS INC | Healthcare | $4.52B | 1.64% |
16CDNA | CAREDX INC | Healthcare | $4.19B | 1.52% |
17CRSP | CRISPR THERAPEUTICS AG | Healthcare | $4.13B | 1.50% |
18IOVA | IOVANCE BIOTHERAPEUTICS INC | Healthcare | $3.53B | 1.28% |
19ARQT | ARCUTIS BIOTHERAPEUTICS INC | Healthcare | $3.48B | 1.26% |
20IRTC | IRHYTHM HOLDINGS INC | Healthcare | $3.15B | 1.14% |
21ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $3.14B | 1.14% |
22ATRC | ATRICURE INC | Healthcare | $2.85B | 1.03% |
23BEAM | BEAM THERAPEUTICS INC | Healthcare | $2.49B | 0.90% |
24BKD | BROOKDALE SENIOR LIVING INC | Healthcare | $2.14B | 0.78% |
25BHVN | BIOHAVEN LTD | Healthcare | $2.13B | 0.77% |
26SUPN1 | SUPERNUS PHARMACEUTICALS INC | Healthcare | $2.11B | 0.77% |
27VCYT | VERACYTE INC | Healthcare | $1.99B | 0.72% |
28HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.98B | 0.72% |
29BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $1.98B | 0.72% |
30ASTH | ASTRANA HEALTH INC | Healthcare | $1.77B | 0.64% |
31INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.75B | 0.64% |
32SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.72B | 0.62% |
33NRIX | NURIX THERAPEUTICS INC | Healthcare | $1.70B | 0.62% |
34SLS | SELLAS LIFE SCIENCES GROUP INC | Healthcare | $1.62B | 0.59% |
35GENB | GENERATE BIOMEDICINES INC | Healthcare | $1.61B | 0.59% |
36ABSI | ABSCI CORP | Healthcare | $1.57B | 0.57% |
37WGS | GENEDX HOLDINGS CORP | Healthcare | $1.55B | 0.56% |
38ADRX | ADARX PHARMACEUTICALS INC | Healthcare | $1.52B | 0.55% |
39NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.48B | 0.54% |
40NVAX | NOVAVAX INC | Healthcare | $1.45B | 0.52% |
41AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.44B | 0.52% |
42PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.44B | 0.52% |
43GPCR | STRUCTURE THERAPEUTICS INC | Healthcare | $1.42B | 0.52% |
44OCUL | OCULAR THERAPEUTIX INC | Healthcare | $1.38B | 0.50% |
45MLYS | MINERALYS THERAPEUTICS INC | Healthcare | $1.37B | 0.50% |
46NVCR | NOVOCURE LTD | Healthcare | $1.37B | 0.50% |
47INVA | INNOVIVA INC | Healthcare | $1.35B | 0.49% |
48URGN | UROGEN PHARMA LTD | Healthcare | $1.29B | 0.47% |
49CMPS | COMPASS PATHWAYS PLC | Healthcare | $1.29B | 0.47% |
50PNTG | PENNANT GROUP INC | Healthcare | $1.26B | 0.46% |
51TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.22B | 0.44% |
52NUTX | NUTEX HEALTH INC | Healthcare | $1.18B | 0.43% |
53FRNM | FREENOME INC | Healthcare | $1.14B | 0.41% |
54VSTM | VERASTEM INC | Healthcare | $1.06B | 0.39% |
55CTY | CITY THERAPEUTICS INC | Healthcare | $955M | 0.35% |
56AORT | ARTIVION INC | Healthcare | $947M | 0.34% |
57BVS | BIOVENTUS INC | Healthcare | $915M | 0.33% |
58OMDA | OMADA HEALTH INC | Healthcare | $912M | 0.33% |
59HSTM | HEALTHSTREAM INC | Healthcare | $867M | 0.31% |
60RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $860M | 0.31% |
61SNDX | SYNDAX PHARMACEUTICALS INC | Healthcare | $859M | 0.31% |
62GLUE | MONTE ROSA THERAPEUTICS INC | Healthcare | $796M | 0.29% |
63ALMS | ALUMIS INC | Healthcare | $793M | 0.29% |
64OBX | OBSIDIAN THERAPEUTICS INC | Healthcare | $771M | 0.28% |
65QDEL | QUIDELORTHO CORP | Healthcare | $729M | 0.26% |
66CTKB | CYTEK BIOSCIENCES INC | Healthcare | $722M | 0.26% |
67JANX | JANUX THERAPEUTICS INC | Healthcare | $703M | 0.26% |
68KURA | KURA ONCOLOGY INC | Healthcare | $683M | 0.25% |
69AVBP | ARRIVENT BIOPHARMA INC | Healthcare | $676M | 0.25% |
70DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $663M | 0.24% |
71CGEM | CULLINAN THERAPEUTICS INC | Healthcare | $662M | 0.24% |
72MYGN | MYRIAD GENETICS INC | Healthcare | $545M | 0.20% |
73NGNE | NEUROGENE INC | Healthcare | $495M | 0.18% |
74ARVN | ARVINAS INC | Healthcare | $450M | 0.16% |
75PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $418M | 0.15% |
76MASS | 908 DEVICES INC | Healthcare | $407M | 0.15% |
77ASPE | ASPEN NEUROSCIENCE INC | Healthcare | $396M | 0.14% |
78CV | CAPSOVISION INC | Healthcare | $314M | 0.11% |
79KYTX | KYVERNA THERAPEUTICS INC | Healthcare | $311M | 0.11% |
80EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $303M | 0.11% |
81OFIX | ORTHOFIX MEDICAL INC | Healthcare | $283M | 0.10% |
82FTH | FAETH THERAPEUTICS INC | Healthcare | $275M | 0.10% |
83CLPT | CLEARPOINT NEURO INC | Healthcare | $272M | 0.10% |
84ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $243M | 0.09% |
85GLSI | GREENWICH LIFESCIENCES INC | Healthcare | $224M | 0.08% |
86KROS | KEROS THERAPEUTICS INC | Healthcare | $198M | 0.07% |
87ANIK | ANIKA THERAPEUTICS INC | Healthcare | $185M | 0.07% |
88INGN | INOGEN INC | Healthcare | $146M | 0.05% |
89RNA | ATRIUM THERAPEUTICS INC | Healthcare | $128M | 0.05% |
90CUE | CUE BIOPHARMA INC | Healthcare | $127M | 0.05% |
91BDSX | BIODESIX INC | Healthcare | $109M | 0.04% |
92VTVT | VTV THERAPEUTICS INC | Healthcare | $83M | 0.03% |
93NRXS | NEURAXIS INC | Healthcare | $82M | 0.03% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $275.70B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 79% toward Large, 77% toward Growth. +19% unclassified (18 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 93 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T063725 rates=20261113T063725
Measured on the 2026-11 formation date across 93 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators disagree about the verdict, not just the value — the choice of method decides the answer here. Historical VaR gives ratio 2.13 (fail) but Gaussian VaR gives 1.92 (pass). The pass/fail conclusion is an artefact of estimator choice, not a property of the strategy.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 2.8% | -24.2% |
| 3 yearsp.a. | 2.9% | -10.0% |
| 5 yearsp.a. | -13.2% | -22.4% |
| 10 yearsp.a. | 4.9% | -6.9% |
| Since inceptionp.a. | 8.6% | -1.0% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 5.5% | -21.9% |
| 2025 | 0.5% | -13.9% |
| 2024 | -5.7% | 12.9% |
| 2023 | -3.5% | -26.9% |
| 2022 | -48.2% | -48.1% |
| 2021 | 21.0% | 35.0% |
| 2020 | 44.7% | 1.7% |
| 2019 | 25.9% | 14.6% |
| 2018 | 4.4% | 2.3% |
| 2017 | 37.3% | -2.1% |
| 2016 | -19.2% | 1.6% |
| 2015 | -11.9% | -14.7% |
| 2014 | 45.1% | 19.7% |
| 2013 | 49.5% | 5.1% |
| 2012 | 31.6% | 18.8% |
| 2011 | -1.3% | -1.2% |
| 2010 | 9.6% | -2.4% |
| 2009 | 55.7% | 41.6% |
| 2008 | -23.3% | 11.5% |
| 2007 | 4.2% | -10.9% |
| 2006 | 14.6% | 7.6% |
| 2005 | -2.0% | -11.7% |
| 2004 | 8.4% | 7.0% |
| 2003 | 59.6% | 18.4% |
| 2002 | -34.6% | 10.9% |
| 2001 | 19.7% | 47.7% |
| 2000 | 12.3% | -55.2% |
| 1999 | 35.0% | 8.1% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare Short-Term Reversal Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Short-Term Reversal signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.